Rapid health technology evaluation of entecavir for the treatment of chronic hepatitis B
Objective To evaluate the effectiveness,safety,and economics of entecavir in the treatment of chronic hepa-titis B.Methods The Cochrane Library,Science Direct,PubMed,Embase,SinoMed,CNKI,Wanfang Data,VIP databases,and health technology assessment websites were searched by computer.The literature on entecavir for the treatment of chronic HBV infection was collected and analyzed from the inception of the database until August,2023.Two researchers evaluated the quality according to the corresponding criteria and conducted a comprehensive analysis of the obtained results.Results A total amount of 33 literature entries were included in this study,including 1 HTA report,25 systematic reviews/meta-analyses,and 7 pharmacoeconomic studies.In terms of effectiveness,the HBV-DNA negative conversion rate and ALT normalization rate of entecavir were better than those of adefovir,and entecavir had an excellent effect on preventing HBV reactivation.In terms of safety,the adverse reactions of entecavir were generally mild,and the overall incidence were low,there existed no significant difference compared with other drugs such as lamivudine and adefovir.In terms of pharmacoeconomics,compared with patients without antiviral drug treatment,oral entecavir had a better cost performance,and entecavir monotherapy had more economic advantages compared with combination with other therapeutic drugs.Conclusion For chronic hepatitis B treat-ment,entecavir can achieve excellent outcomes with a low safety risk and decent cost-effectiveness.
entecavirchronic hepatitis Beffectivenesssafetyeconomicsrapid health technology assessment
NETL
NSTL
万方数据
